Abstract
To compare the effect of ritonavir on plasma amprenavir pharmacokinetics, healthy adults received either fosamprenavir (700 mg twice a day [BID]) or amprenavir (600 mg BID) alone and in combination with ritonavir (100 mg BID). Ritonavir increased plasma amprenavir pharmacokinetic parameters to a similar extent when coadministered with either fosamprenavir or amprenavir.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Area Under Curve
-
Carbamates / administration & dosage
-
Carbamates / pharmacology*
-
Cross-Over Studies
-
Drug Interactions
-
Drug Therapy, Combination
-
Female
-
Furans
-
HIV Protease Inhibitors / pharmacology*
-
Humans
-
Male
-
Middle Aged
-
Organophosphates / administration & dosage
-
Organophosphates / pharmacokinetics*
-
Ritonavir / administration & dosage
-
Ritonavir / pharmacology*
-
Sulfonamides / administration & dosage
-
Sulfonamides / pharmacokinetics*
-
Sulfonamides / pharmacology*
Substances
-
Carbamates
-
Furans
-
HIV Protease Inhibitors
-
Organophosphates
-
Sulfonamides
-
amprenavir
-
Ritonavir
-
fosamprenavir